Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
P2RY11 Biologics Sequence Review Report 2026: P2Y purinoceptor 11 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
P2RY11 Biologics Sequence Review Report 2026: P2Y purinoceptor 11 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RY11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
P2RY10 Biologics Sequence Review Report 2026: Putative P2Y purinoceptor 10 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
P2RY10 Biologics Sequence Review Report 2026: Putative P2Y purinoceptor 10 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RY10 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
P2RY6 Biologics Sequence Review Report 2026: P2Y purinoceptor 6 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
P2RY6 Biologics Sequence Review Report 2026: P2Y purinoceptor 6 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RY6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
P2RY1 Biologics Sequence Review Report 2026: P2Y purinoceptor 1 Similarity and Patent-Risk Signals
8 min read
P2RY1 Biologics Sequence Review Report 2026: P2Y purinoceptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RY1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
P2RX7 Biologics Sequence Review Report 2026: P2X purinoceptor 7 Similarity and Patent-Risk Signals
8 min read
P2RX7 Biologics Sequence Review Report 2026: P2X purinoceptor 7 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
P2RX5 Biologics Sequence Review Report 2026: P2X purinoceptor 5 Similarity and Patent-Risk Signals
8 min read
P2RX5 Biologics Sequence Review Report 2026: P2X purinoceptor 5 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
P2RX4 Biologics Sequence Review Report 2026: P2X purinoceptor 4 Similarity and Patent-Risk Signals
8 min read
P2RX4 Biologics Sequence Review Report 2026: P2X purinoceptor 4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
P2RX3 Biologics Sequence Review Report 2026: P2X purinoceptor 3 Similarity and Patent-Risk Signals
8 min read
P2RX3 Biologics Sequence Review Report 2026: P2X purinoceptor 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
P2RX2 Biologics Sequence Review Report 2026: P2X purinoceptor 2 Similarity and Patent-Risk Signals
8 min read
P2RX2 Biologics Sequence Review Report 2026: P2X purinoceptor 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
P2RX1 Biologics Sequence Review Report 2026: P2X purinoceptor 1 Similarity and Patent-Risk Signals
8 min read
P2RX1 Biologics Sequence Review Report 2026: P2X purinoceptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OXER1 Biologics Sequence Review Report 2026: Oxoeicosanoid receptor 1 Similarity and Patent-Risk Signals
8 min read
OXER1 Biologics Sequence Review Report 2026: Oxoeicosanoid receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OXER1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
NTF4 Biologics Sequence Review Report 2026: Neurotrophin-4 Similarity and Patent-Risk Signals
8 min read
NTF4 Biologics Sequence Review Report 2026: Neurotrophin-4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NTF4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →